31 results
8-K
EX-99.1
AXLA
Axcella Health Inc.
13 Oct 22
Entry into a Material Definitive Agreement
8:15am
that demonstrate the potential to harness the power of EMMs to tackle prevalent chronic conditions and I believe the company is now well positioned
424B5
AXLA
Axcella Health Inc.
13 Oct 22
Prospectus supplement for primary offering
7:55am
outcome measure of fatigue that has been used in measuring subject impact in fatigue states such as chronic fatigue syndrome. The Clinical Trial
8-K
EX-99.2
AXLA
Axcella Health Inc.
29 Sep 22
Regulation FD Disclosure
9:15am
— Decreasing inflammation Axcella’s clinical data demonstrate the potential to harness the power of EMMs to tackle complex chronic conditions — Improving
8-K
s615 wzzd
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.2
2a87bc1eh8b5hw3tlz1
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.1
bb2fideh0
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
424B5
0k4cukamh1hpv3lfg5p
16 Mar 22
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
w0t6uh122izn n8x
10 Jan 22
Other Events
8:00am
8-K
EX-99.2
s6525vxju15p
6 May 21
Axcella Reports First Quarter Financial Results and Provides Business Update
7:51am
424B4
ym3bzial9767ohfsttz7
14 May 20
Prospectus supplement with pricing info
5:15pm